CompletedNot Applicable

Ovarian Reserve in Crohn's Disease

Turkey (Türkiye)100 participantsStarted 2019-03-01

Plain-language summary

Crohn's disease reduces fertility by inducing inflammation both directly and in the fallopian tubes and ovaries and indirectly through surgical interventions and tubal adhesions associated with disease treatment. Anti-mullerian hormone (AMH) is a reliable indicator of ovarian reserve in women. The aim of this study was to compare serum AMH levels in women with Crohn's disease and healthy controls. In this study, the investigators aimed to investigate AMH and ovarian capacity in the study group with crohn's disease and in the control group without disease.

Who can participate

Age range18 Years – 40 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * crohn's disease; * reproductive age women Exclusion Criteria: * Over 40 years old, * a previous ovarian resection; * renal failure (serum creatinine levels N1.2 mg / dL);suspicion of malignancy; * the presence of hereditary or acquired hematological disease; * pregnancy; * current lactation; * the presence of a serious comorbid chronic disease; * cirrhosis originating from chronic liver disease; * abnormal thyroid function tests; * a known serious psychological problem; * presence of alcoholism and male sex.

What they're measuring

AMH levels

Timeframe: 1 MONTH

Trial details

NCT IDNCT03897400

SponsorKanuni Sultan Suleyman Training and Research Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-09-01

View on ClinicalTrials.gov More Crohn Disease trials